Edward T. Mathers
Sits on 5 boards. Overboarded · 5 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 5
- Current seats
- 5
- Board service
- 15 years
- Director since
- 2023
15 years of board service in total across 5 boards, counting each seat separately. Longest: Rhythm Pharmaceuticals Inc., 3 years.
Rhythm Pharmaceuticals Inc.
Director
OnKure Therapeutics Inc.
Director
Senti Biosciences Holdings Inc.
Director
Trevi Therapeutics Inc.
Director
MBX Biosciences Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 12, 2026 | Rhythm Pharmaceuticals Inc. | Other | +4,199 | — | — |
| Mar 10, 2026 | Korro Bio Inc. | Open-market purchase | +207,100 | $11.11 | $2,300,881 |
| Mar 2, 2026 | Rhythm Pharmaceuticals Inc. | Other | +4,198 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,619,240 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,370,168 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +1,370,168 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Derivative conversion | +737,962 | — | — |
| Feb 9, 2026 | SpyGlass Pharma Inc. | Open-market purchase | +937,500 | $16.00 | $15,000,000 |
| Dec 31, 2025 | OnKure Therapeutics Inc. | Grant or award | +3,911 | — | — |
| Sep 30, 2025 | OnKure Therapeutics Inc. | Grant or award | +4,125 | — | — |
| Jun 30, 2025 | OnKure Therapeutics Inc. | Grant or award | +4,694 | — | — |
| Jun 18, 2025 | Rhythm Pharmaceuticals Inc. | Option exercise | +4,000 | — | — |
| Mar 31, 2025 | OnKure Therapeutics Inc. | Grant or award | +2,580 | — | — |
| Sep 16, 2024 | MBX Biosciences Inc. | Derivative conversion | +1,023,103 | — | — |
| Sep 16, 2024 | MBX Biosciences Inc. | Derivative conversion | +2,091,383 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.